SCHEMBL95950

SCHEMBL95950

[O]CCCCOc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 2/20 0.76
HDAC1 Q13547 3/20 0.59
HDAC2 Q92769 3/20 0.59
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59
TAAR1 Q96RJ0 1/20 0.54
ALDH1A1 P00352 1/20 0.54
RECQL P46063 1/20 0.54
DRD2 P14416 1/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
LTA4H P09960 2/20 0.53
HTR1B P28222 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007516 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1007289 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1006072 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL97258 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1006823 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1006273 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1004356 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1004973 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1008922 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4
SCHEMBL1005798 0.98 KCNA3 (0.73) KCNA3HDAC1HDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171455-A1 Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-19 US claimed
EP-2717871-A2 REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION The Regents of the University of California (US) 2014-04-16 EP claimed
WO-2012170917-A2 REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-13 WO claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
CN-110446976-B Photosensitive resin composition 旭化成株式会社 2023-03-24 CN disclosed
CN-112534351-A Photosensitive resin composition and method for forming resist pattern 旭化成株式会社 2021-03-19 CN disclosed
CN-112368642-A Photosensitive resin composition and method for forming resist pattern 旭化成株式会社 2021-02-12 CN disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
WO-2020032133-A1 PHOTOSENSITIVE RESIN COMPOSITION AND METHOD FOR FORMING RESIST PATTERN 旭化成株式会社 2020-02-13 WO disclosed
CN-110446976-A Photosensitive resin composition ASAHI CHEMICAL IND 2019-11-12 CN disclosed
CN-105408325-B cyanotriazole compounds 大塚制药株式会社 2019-10-22 CN disclosed
WO-1993011669-A1 USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS BASF AKTIENGESELLSCHAFT (DE) 1993-06-24 WO disclosed
EP-0525123-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES. UPJOHN CO (US) 1993-02-03 EP disclosed
US-5145952-A Blue, textiles BASF AKTIENGESELLSCHAFT (DE) 1992-09-08 US disclosed
EP-0489877-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 2-AMINO-6-PHENYL-4H-PYRAN-4-ONES. UPJOHN CO (US) 1992-06-17 EP disclosed
WO-1992000290-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 2-AMINO-6-PHENYL-4H-PYRAN-4-ONES THE UPJOHN COMPANY (US) 1992-01-09 WO disclosed
WO-1991019707-A2 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1991-12-26 WO disclosed
EP-0459983-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES PHARMACIA & UPJOHN COMPANY (US) 1991-12-11 EP disclosed
EP-0381974-A2 Thiophene azo dyes with a coupling component based on m-phenylene diamine BASF Aktiengesellschaft (DE) 1990-08-16 EP disclosed
WO-1990006921-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1990-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KCNA3 2519/4885HDAC1 177/4885HDAC2 487/4885
US-20140171455-A1 Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition KCNMA1, KCNN1, KCNN3 KCNA3 13/4885HDAC1 786/4885HDAC2 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.